Statements (41)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
prostaglandin analogue |
| gptkbp:approvedBy |
gptkb:European_Union
gptkb:Japan gptkb:United_States 2008 (Japan) 2012 (US) |
| gptkbp:ATCCode |
S01EE05
|
| gptkbp:brand |
Taflotan
Zioptan |
| gptkbp:CASNumber |
209860-87-7
|
| gptkbp:contraindication |
hypersensitivity to tafluprost
|
| gptkbp:eliminationHalfLife |
45 minutes (approximate, in plasma)
|
| gptkbp:form |
preservative-free eye drops
|
| gptkbp:hasMolecularFormula |
C25H34F2O5
|
| gptkbp:hasSMILES |
CC(C)CCC[C@H](C)C1CCC2C1C(=O)OCC2COC(=O)C=C(C)C3=CC(=CC(=C3)F)F
|
| https://www.w3.org/2000/01/rdf-schema#label |
Tafluprost
|
| gptkbp:KEGGID |
D08541
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:marketedAs |
gptkb:Merck
gptkb:Santen_Pharmaceutical |
| gptkbp:mechanismOfAction |
prostaglandin F2α receptor agonist
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:pregnancyWarning |
use only if potential benefit justifies potential risk
|
| gptkbp:prescriptionStatus |
Rx-only
|
| gptkbp:PubChem_CID |
CHEMBL1201832
8030444 9854882 DB06217 |
| gptkbp:reduces |
intraocular pressure
|
| gptkbp:routeOfAdministration |
ophthalmic (eye drops)
|
| gptkbp:sideEffect |
eye pain
eye irritation conjunctival hyperemia |
| gptkbp:storage |
refrigerate before opening
store at room temperature after opening |
| gptkbp:UNII |
Q1J8A4N6F2
|
| gptkbp:usedFor |
treatment of ocular hypertension
treatment of open-angle glaucoma |
| gptkbp:bfsParent |
gptkb:Santen_Pharmaceutical
|
| gptkbp:bfsLayer |
6
|